Download Files:

Desmethyl Erlotinib-d4

$1,120

Only 1000 item(s) left in stock.

Products Details

Product Description

– Desmethyl Erlotinib-d4 is the deuterium labeled Desmethyl Erlotinib. Desmethyl Erlotinib (OSI-420 free base) is an active metabolite of Erlotinib. Erlotinib is a potent EGFR tyrosin kinase inhibitor[1][2]. Desmethyl Erlotinib-d4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Web ID

– HY-13256AS

Shipping

– Room temperature

Applications

– Cancer-programmed cell death

Molecular Formula

– C21H17D4N3O4

References

– [1]Thappali SR, et al. Simultaneous Determination of Celecoxib, Erlotinib, and its Metabolite Desmethyl-Erlotinib (OSI-420) in Rat Plasma by Liquid chromatography/Tandem Mass Spectrometry with Positive/Negative Ion-Switching Electrospray Ionisation.Sci Pharm. 2012 Jul-Sep;80(3):633-46.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

CAS Number

– 1216420-11-9

Molecular Weight

– 383.43

SMILES

– N(C=1C2=C(C=C(OCCOC)C(OCCO)=C2)N=CN1)C3=C(C(C#C)=C(C(=C3[2H])[2H])[2H])[2H]

Clinical Information

– No Development Reported

Research Area

– Cancer

Solubility

– 10 mM in DMSO

Target

– Drug Metabolite;Isotope-Labeled Compounds

Pathway

– Metabolic Enzyme/Protease;Others

Product type

– Isotope-Labeled Compounds

Disclaimer: All products are for research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.